MH WK 7

Schizophrenia: Subtypes and Core Features

  • Disorganized schizophrenia:
    • Thoughts, feelings, and behavior are incongruent; easy to spot due to lack of coherence between cognition, affect, and actions. Viewed by laypeople as a \'weirdo\' because of mismatch between what person thinks, feels, and does.
  • Paranoid type:
    • Presence of multiple schizophrenia symptoms with prominent paranoia (delusions, persecution ideas).
  • Catatonic schizophrenia:
    • Two phases: the phase of catatonia (stupor) and the phase of excitement.
    • Phase 1: stupor
    • Client appears statue-like; rigid muscles, immobility, mute, apathetic.
    • Muscular contractions; patient immobile and unresponsive; observation needed for immobility precautions.
    • In the 2/4 stage (stage of stupor), observe precautions for immobility and potential complications.
    • Phase 2: excitement
    • Sudden release/active movement after a period of immobility; potential trauma for staff due to abrupt movements.
  • Undifferentiated and Residual schizophrenia:
    • Undifferentiated: exhibits features of several categories; not fitting clearly into a single subtype.
    • Residual schizophrenia: acute symptoms are managed but residual symptoms persist (impaired socialization, reduced ability to interact normally).
    • Acute symptoms include paranoia and hallucinations; residual phase marks lower functional status but some stability.
  • Classic clinical analogy:
    • The Beautiful Mind example: residual phase after acute symptoms allows functioning (e.g., professor returning to teaching); discharge when patient is functional and safe though symptoms persist.

Nursing Diagnoses in Schizophrenia (overview)

  • Danger to self
    • Risk of suicidality due to delusions or hallucinations; to be discussed in context of depressive episodes and suicide risk later.
  • Danger to others
    • Violence risk related to hallucinations (e.g., persecutory commands) or paranoid delusions; implement safety measures and violence risk assessment.
  • Disturbed sensory perception (hallucinations)
    • Approach: acknowledge feelings, assess reality without arguing; distinguish perception from reality; provide validation of fear while clarifying actual environment.
  • Disturbed thought processes (delusions, paranoia)
    • Manage paranoia with structured, non-threatening interactions; avoid challenging delusions directly; use reality orientation and supportive communication.
  • Impaired verbal communication
    • Some patients may be nonverbal or have reduced speech but can still understand; continue verbal engagement.
  • Social isolation
    • Paranoia can lead to withdrawal; begin with one-on-one trust-building before gradual socialization in groups.
  • Self-care deficit (hygiene, grooming, nutrition, etc.)
    • Paranoia can lead to avoidance of showers, meals, and self-care routines; implement supportive strategies.

Paranoia-Specific Nursing Approaches

  • Before approaching: knock and announce presence; stay by the door or foot of the bed; gain eye contact gradually.
  • Introduce yourself clearly: e.g., "My name is Virtu, I am your nurse for the day."
  • Explain purpose and steps before interacting: what you will do, what you will check (IV site, etc.).
  • Maintain eye contact without staring; establish initial trust before approaching.
  • Medication administration considerations for paranoid patients:
    • Medications should be sealed, not unsealed in front of the patient; administer one dose at a time.
    • For liquids and suspensions, keep sealed cups and ensure doses are shown one at a time; return sealed containers after administration.
    • Do not unseal the entire medication pack in front of the patient; use individually packed doses.
    • For injections, ensure routine medications are given in the patient\'s room with a Dutch door policy in the site; always show vial/ampule before drawing up.
  • Cheeking, pocketing, and spitting precautions:
    • After administration, observe for cheeking (placing medication in cheek), pocketing, or spitting; do not discard cups immediately; observe for concealment.
    • If suspected, document and involve pharmacy for dose verification and consider alternative administration routes if safety concerns persist.
  • Communication with paranoid patients:
    • Do not argue or contradict the delusion; acknowledge fear and focus on feelings: "You sound scared. I understand that you feel scared."
    • Present reality non-confrontationally: avoid saying \'you don\'t hear\' or \"that isn\'t real.\" Instead, reflect feelings and provide a safe environment.
    • Example phrases:
    • "I hear you’re worried the food is poisoned. I will keep your tray here and check with the kitchen. I will stay with you while you eat."
  • Paranoia and meal management:
    • If patient believes water/food is poisoned, avoid tasting or proving otherwise; keep tray in view, offer safe accommodations (e.g., staff-tray presence) to reassure safety.
    • When meals present, monitor for refusal; use strategies like sharing staff meals to demonstrate safety of food.
  • Safety planning during discharge for paranoid patients:
    • Ensure ongoing support, socialization, and monitoring; plan for follow-up visits and therapy.

Catatonia: Phases, Physiologic Priorities, and Nursing Interventions

  • Catatonia as a two-phase condition: stupor and excitement.
  • Phase 1: stupor (statue-like, immobile)
    • Features: immobility, rigidity, contracted muscles, mutism, apathy.
    • Physiologic risk: complications of immobility (pressure ulcers, pneumonia, constipation, urinary retention, venous thromboembolism).
    • Nursing priorities: preserve physiologic integrity; implement pressure sore precautions; consider egg-crate mattress; passive range-of-motion exercises; monitor vital signs and respiration; consider urinary catheter only if ordered.
  • Phase 2: excitement (post-stupor release with active, sometimes violent, movement)
    • Features: sudden, involuntary movements; shouting; potential aggression.
    • Interventions: anticipate risk of harm; use restraints only when medically necessary and as ordered by a physician; be prepared for emergency interventions if agitation escalates.
  • Swallow evaluation in catatonia:
    • Before feeding, obtain a swallow evaluation from Speech Therapy to prevent choking due to altered muscle tone.
  • Mobility assistance in catatonia:
    • Act as a facilitator to help patient out of bed and through gentle guided movement; use a stepwise approach (sit, stand, walk with support) with cooperation from CNAs or staff; ensure safety with assistive devices.
  • Primary focus: physiological integrity first; later, psychosocial rehabilitation.
  • When acute catatonia symptoms subside, shift to psychosocial supports: family education, relapse prevention, and community reintegration.

Management of Psychotic Symptoms and Medication Strategy (Pharmacology overview)

  • Dopamine hypothesis in schizophrenia: dopamine dysregulation is central; antipsychotics target dopamine pathways.
  • Two broad classes of antipsychotics:
    • Typical (first-generation): old generation; examples include ext{haloperidol}, ext{chlorpromazine} (Thorazine). Often used for acute agitation and positive symptoms; higher risk of extrapyramidal symptoms (EPS).
    • Atypical (second-generation): newer generation; examples include ext{olanzapine (Zyprexa)}, ext{risperidone (Risperdal)}, ext{clozapine (Clozaril)}, ext{ziprasidone (Geodon)}, etc. Typically associated with lower EPS but higher risk of metabolic syndrome.
  • Positive vs negative symptoms (useful framework):
    • Positive symptoms (e.g., delusions, hallucinations, disorganized speech, aggression) are prominent with typical antipsychotics and/or acute exacerbations; analogy: having a lot of money triggers exuberant behavior.
    • Negative symptoms (e.g., flat affect, anhedonia, avolition, lack of grooming) are more persistent and may respond differently to atypicals (Restoration of motivation and affect is slower).
  • Antipsychotic choice by symptom profile:
    • Typical agents are often used for acute agitation and prominent positive symptoms (PRN administration). Commonly prescribed as PRN for severe agitation or acute episodes: e.g., 5 ext{ mg} Haldol ext{q4h} PRN for severe agitation.
    • Atypical agents are commonly used for maintenance with fewer EPS and potential metabolic considerations.
  • Metabolic syndrome and monitoring (on initiation and ongoing):
    • Antipsychotics may cause metabolic syndrome; routine baseline/ongoing labs include:
    • Blood glucose / A1C: ext{A1C}, fasting glucose
    • Lipids: ext{lipid panel} (HDL, LDL, triglycerides)
    • Weight and height (to calculate BMI): baseline and monthly thereafter for long-term use
    • Blood pressure: monitor for hypertension
    • Monitoring rationale: helps detect obesity, diabetes, dyslipidemia, hypertension—cardiometabolic risks associated with antipsychotics.
  • Extrapyramidal symptoms (EPS) and tardive dyskinesia (TD):
    • EPS: akinesia, akathisia, dystonia, and oculogyric crisis are common with typical antipsychotics; prevention often includes concurrent diphenhydramine (Benadryl) or other anticholinergics as ordered.
    • Signs and progression of tardive dyskinesia (TD): early tongue movements, then mouth, cheeks, neck, shoulders, arms; TD is often irreversible if not detected early; early recognition and pharmacy consultation are critical.
    • Oculogyric crisis: eyes roll upward; treat promptly with Benadryl; acknowledge and reassure patient.
    • Management philosophy: monitor MAR for high-dose PRNs of haloperidol or other typicals; use Benadryl to mitigate EPS where appropriate; consider switch to atypicals when feasible to minimize EPS risk.
  • Neuroleptic Malignant Syndrome (NMS): a critical emergency;
    • Symptoms: fever, encephalopathy, autonomic instability, severe muscular rigidity; markedly elevated CPK (creatine phosphokinase).
    • Action: emergency hospitalization; obtain CPK; stop antipsychotics; hydrate; monitor organ function; transfer to ICU if needed.
  • Clozapine (Clozaril): a special case in schizophrenia management
    • Clozapine is a potent atypical antipsychotic used as a last-resort agent due to risk of agranulocytosis (severe neutropenia).
    • WBC monitoring protocol:
    • Before starting Clozapine, obtain a complete blood count (CBC) with white blood cell count (WBC).
    • The pharmacist reviews WBC results; if WBC is within normal range, a dose is loaded into the dispensing device; if abnormal, hold the dose.
    • Monitoring frequency: typically weekly WBC checks when starting; weekly dosing with discharge planning for ongoing monitoring after hospital discharge.
    • Upon discharge, coordinate with a physician to ensure ongoing WBC monitoring and infection monitoring; if signs of infection occur, notify clinician immediately due to agranulocytosis risk.
    • Dispenser and monitoring details:
    • Clozapine is loaded into a dispensing device only after WBC results are reviewed and approved; the patient receives weekly doses on the same day after CBC check and pharmacy approval.
    • Practical considerations:
    • Educate patient about infection signs; prioritize infection screening and prompt reporting.
    • On discharge, establish a plan for regular CBCs through outpatient providers.
  • Ziprasidone (Geodon) and absorption considerations
    • Geodon must be taken with a full meal (approximately 500 calories) for proper absorption; a snack is insufficient.
  • Rationale for combination therapies and monitoring in practice
    • Co-prescription strategies (e.g., antipsychotic with diphenhydramine) are used to mitigate EPS; monitor for interactions and side effects.
    • Regular metabolic screening is essential due to metabolic risks associated with many antipsychotics; adjust therapy based on lab results and clinical status.

Schizophrenia: Practical Nursing Considerations and Discharge Planning

  • Medication administration logistics for paranoid patients
    • Use sealed, individually packed doses; do not unseal multiple doses at once; mix of tablets and liquids should be dispensed in sealed containers and opened only at the bedside, one dose at a time.
    • For injections and routine meds, ensure dosing is performed at the patient\'s site with transparent pact handling; consider patient safety by showing vial/ampule to patient prior to drawing, and avoid any appearance of impropriety.
  • Monitoring for cheeking and medication safety
    • After administration, observe for \'cheeking\' and other concealment methods; if cheeking is suspected, document and escalate to pharmacy and physician as appropriate.
  • Paranoia-focused communication tips
    • Narrative technique: acknowledge fear, not the delusion; keep the patient informed of actions to be performed; use calm, clear statements; avoid arguing about the delusion.
  • Nursing management of social integration
    • Begin with one-on-one trust-building; gradually introduce small groups, then larger groups to improve socialization while minimizing distress.
  • Early signs of relapse and relapse prevention
    • After stabilization, continue monitoring for acute symptoms; maintain follow-up with psychiatry; plan relapse prevention strategies and psychosocial supports.

Rehabilitation, Discharge, and Follow-Up for Psychosis

  • Ongoing psychosocial therapy and community reintegration
    • Encourage vocational rehabilitation, group activities, and community-based programs.
    • Recognize that schizophrenia management is ongoing; periods of remission and exacerbation are common.
  • Discharge planning and safety planning
    • Develop a comprehensive discharge plan including medications, psychoeducation, follow-up appointments, safety plan, and crisis resources.
    • Use Columbia Suicide Severity Rating Scale (CSSRS) as standard suicide risk assessment; maintain safety planning during discharge.
  • Suicide risk assessment and safety plan (in-hospital and post-discharge)
    • Directly assess suicide risk with questions such as:
    • "Are you thinking about suicide?" or more direct variants like:
      • "Are you thinking about dying?" or "Are you thinking about sleeping and not waking up?" or "Are you thinking about ending your life?"
    • If positive for risk, implement safety precautions: one-on-one supervision with continuous line of sight (24/7) or irregular, unscheduled rounds if one-to-one staffing is unavailable; position patient in a room near the nurses\' station; consider roommate if safety allows.
    • If there is immediate danger, escalate to emergency services (911) and transfer to higher care; maintain patient safety by removing potential means (sharp objects, belts, cords, etc.).
    • Develop a personalized safety plan with the patient prior to discharge (involves patient consent and signature):
    • Signs and emotions when thinking about suicide; coping strategies; people to contact; hotlines (e.g., 988 in many regions) and crisis resources; friends/family to involve; steps to seek help.
    • After discharge, ensure the patient has ongoing supports and crisis resources; provide written safety plan and ensure the patient understands how to access help quickly.

Depression: Types, Theories, and Nursing Implications

  • Grief and the grief process (Kubler-Ross framework):
    • Denial, Anger, Bargaining, Depression, Acceptance.
    • Grief can be a normal response to loss; anticipatory grief occurs when loss is expected; maladaptive or exaggerated grief can occur with delayed or inhibited responses.
    • Anticipatory grief: prepares for imminent loss; positive for those who accept loss; potentially negative if the person near loss withdraws or disconnects.
  • Depression: major concepts and prevalence
    • Major depressive disorder is a leading cause of disability due to impaired initiative, energy, and activities of daily living.
    • Higher prevalence in women; onset can occur at a young age (even as early as 10 years).
    • Depression can be episodic (single episode or recurrent) or chronic (persistent depressive disorder, dysthymia).
  • Biochemical and neuroendocrine underpinnings
    • Depression: associated with imbalances in serotonin and norepinephrine; some dopamine involvement; thyroid function (TSH) can influence mood.
    • Treatments: antidepressants often target serotonin (SSRI) and norepinephrine (SNRI) reuptake; thyroid involvement can be a contributing factor.
  • Psychoanalytic and learning theories
    • Psychoanalytic theory (Freud): depression reflects anger directed inward (self-blame).
    • Learned helplessness theory: perceived lack of control leads to depressive symptoms; cognitive patterns influence mood.
    • Object-loss theory: loss of a meaningful object/person can precipitate depression.
  • Cognitive theory and therapy
    • Central idea: thoughts influence mood, which in turn affects behavior; cognitive-behavioral therapy (CBT) emphasizes modifying negative thought patterns to improve mood and functioning.
  • Etiology: multifactorial and transactional model
    • No single cause; depression arises from an interplay of biological, psychological, and social factors; the transactional model captures multiple interacting factors.
  • Depressive disorders: common subtypes
    • Major depressive disorder (single episode, recurrent)
    • Persistent depressive disorder (dysthymia)
    • Premenstrual dysphoric disorder (PMDD)
    • Substance/medication-induced depressive disorder
    • Depressive disorder due to another medical condition
    • Seasonal affective disorder (SAD)
    • Postpartum mood disorders (postpartum depression, postpartum psychosis)
  • Assessment and screening tools (informative for clinical workflow)
    • CSSRS (Columbia Suicide Severity Rating Scale): standard for suicide risk assessment in ED and admission.
    • PHQ-9: a common depressive symptom screen used by psychologists.
    • ZIGITACS: another psychiatric assessment tool used by some physicians.
    • CSSRS is commonly used in many hospital settings to assess suicide risk.
  • Depression: clinical features to monitor and manage
    • Core symptoms: anhedonia (loss of pleasure), diminished interest, appetite changes, sleep disturbance, psychomotor changes, fatigue, feelings of worthlessness or excessive guilt, poor concentration, and recurrent thoughts of death.
    • Sleep and appetite disturbances are common; some patients experience hypersomnia and increased sleep; others insomnia; irritability can accompany sleep disturbances.
    • Behavioral impact: decreased energy and initiative lead to poor adherence to routines and social withdrawal.
  • Depression management implications for nursing care
    • Interventions emphasize CBT-based approaches, supportive counseling, encouragement of activity, and small, frequent nutritious meals.
    • Nutrition: for depressive patients, small, frequent, nutrient-dense meals are preferred; avoid heavy meals that can be daunting for low energy and low motivation.
    • Diet considerations: high-fiber, balanced diet; low-carbohydrate approach may be used to manage weight and metabolic concerns; ensure adequate protein and micronutrients.
    • Sleep hygiene: address sleep pattern disturbances; tailor interventions to patient preferences and cultural norms; avoid over-sedation.
    • Psychoeducation and therapy: link to therapy modalities; promote social engagement; plan for gradual reengagement in activities and routines.
  • Postpartum mood disorders and hormonal influences
    • Postpartum mood changes can be hormonally driven; risk of postpartum depression or postpartum psychosis; collaborative care with obstetrics/gynecology and psychiatry is essential.
    • Safety considerations for mothers with newborns; assess risk to baby and mother; ensure appropriate referrals.
  • Cultural considerations in depression assessment
    • Cultural differences influence symptom presentation and help-seeking; some cultures emphasize somatic complaints (body aches, chest pain, palpitations) rather than self-reported mood symptoms; ask targeted questions about sleep, appetite, and energy to uncover mood disturbances.

Key Concepts, Formulas, and Quantitative Details (with LaTeX formatting)

  • Catatonia phases and durations:
    • Catatonia has 2 phases: stupor and excitement; typical observation occurs over several ext{days} (often around 5 days in clinical anecdote examples).
  • Medication-related terms and dosing examples:
    • Haloperidol 5 mg PRN every 4\,\text{h} for severe agitation: ext{Haldol } 5\,\text{mg} \; \text{PRN every } 4\,\text{hours}.
    • Ziprasidone (Geodon) absorption requires a full meal of approximately 500\ \text{calories} for proper absorption.
    • Common PRN and routine regimens may include: ext{Haldol } 5\,\text{mg} \; \text{Q4h PRN}; \text{olanzapine} 5 mg BID (example). Numbers are hospital-specific but illustrate typical patterns.
  • Monitoring parameters for metabolic syndrome (on antipsychotics):
    • Baseline and ongoing: ext{A1C}, ext{lipid panel}, ext{weight}, \text{BMI}, \text{BP}, \text{TSH}.
  • Safety and monitoring for Clozapine:
    • WBC monitoring schedule: weekly CBC with WBC; dose loading into dispensing device after normal WBC; continued weekly CBCs during maintenance; infection signs prompt clinician notification due to agranulocytosis risk.
  • Suicidal risk assessment and safety planning: key steps (in bullets above) summarized as:
    • Direct questioning about suicidality; if positive, implement safety plan: one-on-one supervision, line-of-sight, irregular rounds if needed, room near nurses\' station, consider roommate if safe, and develop a discharge safety plan with the patient (including a written, signed plan and crisis resources). A hotline reference: 988 (suicide crisis line).

Connections to Foundational Principles and Real-World Relevance

  • The distinction between positive and negative symptoms helps clinicians target treatment strategies and anticipate side effects. Positive symptoms (psychosis) are often responsive to antipsychotics; negative symptoms require broader psychosocial interventions and sometimes different pharmacologic approaches.
  • Etiological models (biochemical, psychoanalytic, learning, cognitive, and transactional) underscore the multifactorial nature of depression and psychosis. This supports a holistic approach combining pharmacology, psychotherapy, and social supports.
  • The metabolic syndrome risk associated with antipsychotics highlights the need for routine physical health monitoring in psychiatric care, reflecting the integration of mental and physical health.
  • Safety planning and suicide risk assessment are critical components of inpatient and outpatient care, acknowledging that risk can exist in acute and post-discharge settings; transfer of care requires clear communication and structured plans.
  • Cultural sensitivity matters in assessment and treatment; presentations of depression may be somatic in some cultures, which necessitates culturally informed questioning and intervention.

Ethical and Practical Implications

  • Early detection of extrapyramidal symptoms (EPS) and tardive dyskinesia (TD) is essential to prevent irreversible motor changes; clinicians should monitor closely, document signs, and adjust therapy promptly.
  • Cohesive safety planning and ongoing risk assessment protect both patient and staff; one-on-one observation and unsafe environments are vital when suicide risk is present.
  • Informed consent and discharge planning should include a clear, actionable safety plan with crisis resources and contacts; patient engagement in safety planning respects autonomy while ensuring safety.

Important Tools and Resources Mentioned

  • CSSRS: Columbia Suicide Severity Rating Scale (standard screening tool for suicide risk in ED/admission)
  • PHQ-9: Depression screening tool used by psychologists
  • ZIGITACS: Psychiatric assessment instrument used by some clinicians
  • 988: Suicide crisis hotline (emergency resource)
  • WBC monitoring for Clozapine due to agranulocytosis risk; weekly CBC checks; ensure coordination with pharmacy and outpatient providers on discharge
  • Nutritional and metabolic monitoring: A1C, lipid panel, BP, weight, height; rationale tied to metabolic syndrome risk from antipsychotics
  • Emphasis on non-confrontational communication with psychotic symptoms; present reality while validating feelings

Notes on Practical Routines and Breaks

  • When working with acutely psychotic patients, structure interactions: approach, explain, and proceed step by step; document patient responses and plan of care.
  • Ensure staff training on recognizing and managing catatonia and NMS; rapid escalation protocols and transfer to ICU when indicated.
  • Continuous education is essential for nurses: understanding first signs of TD allows timely pharmacologic intervention and potentially reverses progression.
  • Rehabilitation and community integration should be incorporated early in care to improve long-term outcomes and reduce relapse risk.

Summary Takeaways

  • Schizophrenia has multiple subtypes with distinct clinical patterns; catatonia requires special attention to physiologic integrity and staged interventions.
  • Antipsychotics come in typical and atypical classes; metabolic and EPS risks necessitate careful monitoring, with Clozapine requiring stringent WBC surveillance.
  • Depression and grief share overlapping features but differ in etiology and trajectory; CBT and structured safety planning are central to management, including proactive suicide risk assessment (CSSRS) and post-discharge safety planning.
  • Safety, clear communication, and coordinated care (psychiatry, nursing, pharmacy, social work, and family) are essential across inpatient and outpatient settings to optimize outcomes for patients with psychotic disorders and depressive illnesses.